NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022

J Natl Compr Canc Netw. 2022 Aug;20(8):866-878. doi: 10.6004/jnccn.2022.0041.


The NCCN Guidelines for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer and other urinary tract cancers (upper tract tumors, urothelial carcinoma of the prostate, primary carcinoma of the urethra). These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines regarding the treatment of non-muscle-invasive bladder cancer, including how to treat in the event of a bacillus Calmette-Guérin (BCG) shortage; new roles for immune checkpoint inhibitors in non-muscle invasive, muscle-invasive, and metastatic bladder cancer; and the addition of antibody-drug conjugates for metastatic bladder cancer.

MeSH terms

  • Administration, Intravesical
  • Carcinoma, Transitional Cell* / pathology
  • Humans
  • Male
  • Neoplasm Invasiveness / pathology
  • Neoplasm Recurrence, Local / pathology
  • Neoplasm Staging
  • Urinary Bladder Neoplasms* / drug therapy
  • Urinary Bladder Neoplasms* / therapy